eagle-i Oregon Health and Science UniversityOregon Health and Science University
See it in Search

Haesun Park Laboratory

Summary:

AIDS vaccine development, HIV/SIV pathogenesis

Affiliations:

People:

Resources:

Reagents

  • anti-CCR5-APC ( Monoclonal antibody reagent )

  • anti-CCR5-PE ( Monoclonal antibody reagent )

  • anti-CCR7 ( Monoclonal antibody reagent )

  • anti-CCR7-APC ( Monoclonal antibody reagent )

  • anti-CCR7-FITC ( Monoclonal antibody reagent )

  • anti-CCR7-PE ( Monoclonal antibody reagent )

  • anti-CD103 ( Monoclonal antibody reagent )

  • anti-CD107α-FITC ( Monoclonal antibody reagent )

  • anti-CD107β-FITC ( Monoclonal antibody reagent )

  • anti-CD11a-APC ( Monoclonal antibody reagent )

  • anti-CD11a-PE ( Monoclonal antibody reagent )

  • anti-CD11b-APC ( Monoclonal antibody reagent )

  • anti-CD11c-APC ( Monoclonal antibody reagent )

  • anti-CD123-PE ( Monoclonal antibody reagent )

  • anti-CD123-TrR(PerCP-Cy5.5) ( Monoclonal antibody reagent )

  • anti-CD127-PE ( Monoclonal antibody reagent )

  • anti-CD134 ( Monoclonal antibody reagent )

  • anti-CD14-FITC ( Monoclonal antibody reagent )

  • anti-CD14-FITC ( Monoclonal antibody reagent )

  • anti-CD14-PE-Cy7 ( Monoclonal antibody reagent )

  • anti-CD159a-PE ( Monoclonal antibody reagent )

  • anti-CD16-FITC ( Monoclonal antibody reagent )

  • anti-CD16-Pacific Blue ( Monoclonal antibody reagent )

  • anti-CD169-PE ( Monoclonal antibody reagent )

  • anti-CD19 ( Monoclonal antibody reagent )

  • anti-CD20-APC-Cy7 ( Monoclonal antibody reagent )

  • anti-CD20-TrR(PerCP-Cy5.5) ( Monoclonal antibody reagent )

  • anti-CD23-ECD(PE-Texas Red) ( Monoclonal antibody reagent )

  • anti-CD25-APC ( Monoclonal antibody reagent )

  • anti-CD25-biotin ( Monoclonal antibody reagent )

  • anti-CD27-PE ( Monoclonal antibody reagent )

  • anti-CD28 ( Monoclonal antibody reagent )

  • anti-CD28-APC ( Monoclonal antibody reagent )

  • anti-CD28-ECD (PE-Texas Red) ( Monoclonal antibody reagent )

  • anti-CD28-FITC ( Monoclonal antibody reagent )

  • anti-CD28-PE ( Monoclonal antibody reagent )

  • anti-CD28-TrR (PerCP-Cy5.5) ( Monoclonal antibody reagent )

  • anti-CD3-TrR (PerCP-Cy5.5) ( Monoclonal antibody reagent )

  • anti-CD3e-Alexa700 ( Monoclonal antibody reagent )

  • anti-CD3ε-APC ( Monoclonal antibody reagent )

  • anti-CD3ε-Pacific Blue ( Monoclonal antibody reagent )

  • anti-CD3ε-PE ( Monoclonal antibody reagent )

  • anti-CD4-AmCyan ( Monoclonal antibody reagent )

  • anti-CD4-APC ( Monoclonal antibody reagent )

  • anti-CD4-APC-Cy7 ( Monoclonal antibody reagent )

  • anti-CD4-FITC ( Monoclonal antibody reagent )

  • anti-CD4-TrR (PerCP-Cy5.5) ( Monoclonal antibody reagent )

  • anti-CD45 ( Monoclonal antibody reagent )

  • anti-CD45-PE ( Monoclonal antibody reagent )

  • anti-CD49d ( Monoclonal antibody reagent )

  • anti-CD56-APC ( Monoclonal antibody reagent )

  • anti-CD56-TrR (PerCP-Cy5.5) ( Monoclonal antibody reagent )

  • anti-CD69-ECD (PE-Texas Red) ( Monoclonal antibody reagent )

  • anti-CD69-PE ( Monoclonal antibody reagent )

  • anti-CD69-PE ( Monoclonal antibody reagent )

  • anti-CD69-TrR (PerCP-Cy5.5) ( Monoclonal antibody reagent )

  • anti-CD8a-Am Cyan ( Monoclonal antibody reagent )

  • anti-CD8a-AmCyan ( Monoclonal antibody reagent )

  • anti-CD8a-APC ( Monoclonal antibody reagent )

  • anti-CD8a-APC-Cy7 ( Monoclonal antibody reagent )

  • anti-CD8a-PE-Cy7 ( Monoclonal antibody reagent )

  • anti-CD8a-TrR (PerCP-Cy5.5) ( Monoclonal antibody reagent )

  • anti-CD8b-ECD (PE-Texas Red) ( Monoclonal antibody reagent )

  • anti-CD95-APC ( Monoclonal antibody reagent )

  • anti-CD95-FITC ( Monoclonal antibody reagent )

  • anti-CD95-PE ( Monoclonal antibody reagent )

  • anti-CD95-PE-Cy7 ( Monoclonal antibody reagent )

  • anti-CXCR4 ( Monoclonal antibody reagent )

  • anti-CXCR5 ( Monoclonal antibody reagent )

  • anti-Foxp3-PE ( Monoclonal antibody reagent )

  • anti-HLA-DR ( Monoclonal antibody reagent )

  • anti-HLA-DR-ECD (PE-Texas Red) ( Monoclonal antibody reagent )

  • anti-HLA-DR-ECD (PE-Texas Red) ( Monoclonal antibody reagent )

  • anti-HLA-DR-FITC ( Monoclonal antibody reagent )

  • anti-HLA-DR-PE-Cy7 ( Monoclonal antibody reagent )

  • anti-IFNγ-APC ( Monoclonal antibody reagent )

  • anti-IFNγ-FITC ( Monoclonal antibody reagent )

  • anti-IL2-APC ( Monoclonal antibody reagent )

  • anti-IL2-PE ( Monoclonal antibody reagent )

  • anti-Integrin B7-APC ( Monoclonal antibody reagent )

  • anti-Integrin B7-PE ( Monoclonal antibody reagent )

  • anti-Ki67-FITC ( Monoclonal antibody reagent )

  • anti-Ki67-PE ( Monoclonal antibody reagent )

  • anti-MIP1B-PE ( Monoclonal antibody reagent )

  • anti-PD-1-PE ( Monoclonal antibody reagent )

  • anti-TCRγδ-FITC ( Monoclonal antibody reagent )

  • anti-TNFα-APC ( Monoclonal antibody reagent )

  • anti-TNFα-FITC ( Monoclonal antibody reagent )

  • anti-TNFα-PE ( Monoclonal antibody reagent )

  • anti-TNFα-PE-Cy7 ( Monoclonal antibody reagent )

  • SIVmac239 Env ( Overlapping peptide peptide library )

    Env #1: MGCLG NQLLI AILLL;
    Env #2: GNQLL IAILL LSVYG;
    Env #3: LIAIL LLSVY GIYCT;
    Env #4: LLLSV YGIYC TLYVT;
    Env #5: VYGIY CTLYV TVFYG;
    Env #6: YCTLY VTVFY GVPAW;
    Env #7: YVTVF YGVPA WRNAT;
    Env #8: FYGVP AWRNA TIPLF;
    Env #9: PAWRN ATIPL FCATK;
    Env #10: NATIP LFCAT KNRDT;
    Env #11: PLFCA TKNRD TWGTT;
    Env #12: ATKNR DTWGT TQCLP;
    Env #13: RDTWG TTQCL PDNGD;
    Env #14: GTTQC LPDNG DYSEV;
    Env #15: CLPDN GDYSE VALNV;
    Env #16: NGDYS EVALN VTESF;
    Env #17: SEVAL NVTES FDAWN;
    Env #18: LNVTE SFDAW NNTVT;
    Env #19: ESFDA WNNTV TEQAI;
    Env #20: AWNNT VTEQA IEDVW;
    Env #21: TVTEQ AIEDV WQLFE;
    Env #22: QAIED VWQLF ETSIK;
    Env #23: DVWQL FETSI KPCVK;
    Env #24: LFETS IKPCV KLSPL;
    Env #25: SIKPC VKLSP LCITM;
    Env #26: CVKLS PLCIT MRCNK;
    Env #27: SPLCI TMRCN KSETD;
    Env #28: ITMRC NKSET DRWGL;
    Env #29: CNKSE TDRWG LTKSI;
    Env #30: ETDRW GLTKS ITTTA;
    Env #31: WGLTK SITTT ASTTS;
    Env #32: KSITT TASTT STTAS;
    Env #33: TTAST TSTTA SAKVD;
    Env #34: TTSTT ASAKV DMVNE;
    Env #35: TASAK VDMVN ETSSC;
    Env #36: KVDMV NETSS CIAQD;
    Env #37: VNETS SCIAQ DNCTG;
    Env #38: SSCIA QDNCT GLEQE;
    Env #39: AQDNC TGLEQ EQMIS;
    Env #40: CTGLE QEQMI SCKFN;
    Env #41: EQEQM ISCKF NMTGL;
    Env #42: MISCK FNMTG LKRDK;
    Env #43: KFNMT GLKRD KKKEY;
    Env #44: TGLKR DKKKE YNETW;
    Env #45: RDKKK EYNET WYSAD;
    Env #46: KEYNE TWYSA DLVCE;
    Env #47: ETWYS ADLVC EQGNN;
    Env #48: SADLV CEQGN NTGNE;
    Env #49: VCEQG NNTGN ESRCY;
    Env #50: GNNTG NESRC YMNHC;
    Env #51: GNESR CYMNH CNTSV;
    Env #52: RCYMN HCNTS VIQES;
    Env #53: NHCNT SVIQE SCDKH;
    Env #54: TSVIQ ESCDK HYWDA;
    Env #55: QESCD KHYWD AIRFR;
    Env #56: DKHYW DAIRF RYCAP;
    Env #57: WDAIR FRYCA PPGYA;
    Env #58: RFRYC APPGY ALLRC;
    Env #59: CAPPG YALLR CNDTN;
    Env #60: GYALL RCNDT NYSGF;
    Env #61: LRCND TNYSG FMPKC;
    Env #62: DTNYS GFMPK CSKVV;
    Env #63: SHFMP KCSKV VVSSC;
    Env #64: PKCSK VVVSS CTRMM;
    Env #65: KVVVS SCTRM METQT;
    Env #66: SSCTR MMETQ TSTWF;
    Env #67: RMMET QTSTW FGFNG;
    Env #68: TQTST WFGFN GTRAE;
    Env #69: TWFGF NGTRA ENRTY;
    Env #70: FNGTR AENRT YIYWH;
    Env #71: RAENR TYIYW HGRDN;
    Env #72: RTYIY WHGRD NRTII;
    Env #73: YWHGR DNRTI ISLNK;
    Env #74: RDNRT IISLN KYYNL;
    Env #75: TIISL NKYYN LTMKC;
    Env #76: LNKYY NLTMK CRRPG;
    Env #77: YNLTM KCRRP GNKTV;
    Env #78: MKCRR PGNKT VLPVT;
    Env #79: RPGNK TVLPV TIMSG;
    Env #80: KTVLP VTIMS GLVFH;
    Env #81: PVTIM SGLVF HSQPI;
    Env #82: MSGLV FHSQP INDRP;
    Env #83: VFHSQ PINDR PKQAW;
    Env #84: QPIND RPKQA WCWFG;
    Env #85: DRPKQ AWCWF GGKWK;
    Env #86: QAWCW FGGKW KDAIK;
    Env #87: WFGGK WKDAI KEVKQ;
    Env #88: KWKDA IKEVK QTIVK;
    Env #89: AIKEV KQTIV KHPRY;
    Env #90: VKQTI VKHPR YTGTN;
    Env #91: IVKHP RYTGT NNTDK;
    Env #92: PRYTG TNNTD KINLT;
    Env #93: GTNNT DKINL TAPGG;
    Env #94: TDKIN LTAPG GGDPE;
    Env #95: NLTAP GGGDP EVTFM;
    Env #96: PGGGD PEVTF MWTNC;
    Env #97: DPEVT FMWTN CRGEF;
    Env #98: TFMWT NCRGE FLYCK;
    Env #99: TNCRG EFLYC KMNWF;
    Env #100: GEFLY CKMNW FLNWV;
    Env #101: YCKMN WFLNW VEDRN;
    Env #102: NWFLN WVEDR NTANQ;
    Env #103: NWVED RNTAN QKPKE;
    Env #104: DRNTA NQKPK EQHKR;
    Env #105: ANQKP KEQHK RNYVP;
    Env #106: PKEQH KRNYV PCHIR;
    Env #107: HKRNY VPCHI RQIIN;
    Env #108: YVPCH IRQII NTWHK;
    Env #109: HIRQI INTWH KVGKN;
    Env #110: IINTW HKVGK NVYLP;
    Env #111: WHKVG KNVYL PPREG;
    Env #112: GKNVY LPPRE GDLTC;
    Env #113: YLPPR EGDLT CNSTV;
    Env #114: REGDL TCNST VTSLI;
    Env #115: LTCNS TVTSL IANID;
    Env #116: STVTS LIANI DWIDG;
    Env #117: SLIAN IDWID GNQTN;
    Env #118: NIDWI DGNQT NITMS;
    Env #119: IDGNQ TNITM SAEVA;
    Env #120: QTNIT MSAEV AELYR;
    Env #121: TMSAE VAELY RLELG;
    Env #122: EVAEL YRLEL GDYKL;
    Env #123: LYRLE LGDYK LVEIT;
    Env #124: ELGDY KLVEI TPIGL;
    Env #125: YKLVE ITPIG LAPTD;
    Env #126: EITPI GLAPT DVKRY;
    Env #127: IGLAP TDVKR YTTGG;
    Env #128: PTDVK RYTTG GTSRN;
    Env #129: KRYTT GGTSR NKRGV;
    Env #130: TGGTS RNKRG VFVLG;
    Env #131: SRNKR GVFVL GFLGF;
    Env #132: RGVFV LGFLG FLATA;
    Env #133: VLGFL GFLAT AGSAM;
    Env #134: LGFLA TAGSA MGAAS;
    Env #135: ATAGS AMGAA SLTLT;
    Env #136: SAMGA ASLTL TAQSR;
    Env #137: AASLT LTAQS RTLLA;
    Env #138: TLTAQ SRTLL AGIVQ;
    Env #139: QSRTL LAGIV QQQQQ;
    Env #140: LLAGI VQQQQ QLLDV;
    Env #141: IVQQQ QQLLD VVKRQ;
    Env #142: QQQLL DVVKR QQELL;
    Env #143: LDVVK RQQEL LRLTV;
    Env #144: KRQQE LLRLT VWGTK;
    Env #145: ELLRL TVWGT KNLQT;
    Env #146: LTVWG TKNLQ TRVTA;
    Env #147: GTKNL QTRVT AIEKY;
    Env #148: LQTRV TAIEK YLKDQ;
    Env #149: VTAIE KYLKD QAQLN;
    Env #150: EKYLK DQAQL NAWGC;
    Env #151: KDQAQ LNAWG CAFRQ;
    Env #152: QLNAW GCAFR QVCHT;
    Env #153: WGCAF RQVCH TTVPW;
    Env #154: FRQVC HTTVP WPNAS;
    Env #155: CHTTV PWPNA SLTPK;
    Env #156: VPWPN ASLTP KWNNE;
    Env #157: NASLT PKWNN ETWQE;
    Env #158: TPKWN NETWQ EWERK;
    Env #159: NNETW QEWER KVDFL;
    Env #160: WQEWE RKVDF LEENI;
    Env #161: ERKVD FLEEN ITALL;
    Env #162: DFLEE NITAL LEEAQ;
    Env #163: ENITA LLEEA QIQQE;
    Env #164: ALLEE AQIQQ EKNMY;
    Env #165: EAQIQ QEKNM YELQK;
    Env #166: QQEKN MYELQ KLNSW;
    Env #167: NMYEL QKLNS WDVFG;
    Env #168: LQKLN SWDVF GNWFD;
    Env #169: NSWDV FGNWF DLASW;
    Env #170: VFGNW FDLAS WIKYI;
    Env #171: WFDLA SWIKY IQYGV;
    Env #172: ASWIK YIQYG VYIVV;
    Env #173: KYTQY GVYIN VGVIL;
    Env #174: YGVYI VVGVI LLRIV;
    Env #175: IVVGV ILLRI VIYIV;
    Env #176: VILLR IVIYI VQMLA;
    Env #177: RIVIY IVQML AKLRQ;
    Env #178: YIVQM LAKLR QGYRP;
    Env #179: MLAKL RQGYR PVFSS;
    Env #180: LRQGY RPVFS SPPSY;
    Env #181: YRPVF SSPPS YFQQT;
    Env #182: FSSPP SYFQQ THIQQ;
    Env #183: PSYFQ QTHIQ QDPAL;
    Env #184: QQTHI QQDPA LPTRE;
    Env #185: IQQDP ALPTR EGKER;
    Env #186: PALPT REGKE RDGGE;
    Env #187: TREGK ERDGG EGGGN;
    Env #188: KERDG GEGGG NSSWP;
    Env #189: GGEGG GNSSW PWQIE;
    Env #190: GGNSS WPWQI EYIHF;
    Env #191: SWPWQ IEYIH FLIRQ;
    Env #192: QIEYI HFLIR QLIRL;
    Env #193: IHFLI RQLIR LLTWL;
    Env #194: IRQLI RLLTW LFSNC;
    Env #195: IRLLT WLFSN CRTLL;
    Env #196: TWLFS NCRTL LSRVY;
    Env #197: SNCRT LLSRV YQILQ;
    Env #198: TLLSR VYQIL QPILQ;
    Env #199: RVYQI LQPIL QRLSA;
    Env #200: ILQPI LQRLS ATLQR;
    Env #201: ILQRL SATLQ RIREV;
    Env #202: LSATL QRIRE VLRTE;
    Env #203: LQRIR EVLRT ELTYL;
    Env #204: REVLR TELTY LQYGW;
    Env #205: RTELT YLQYG WSYFH;
    Env #206: TYLQY GWSYF HEAVQ;
    Env #207: YGWSY FHEAV QAVWR;
    Env #208: YFHEA VQAVW RSATE;
    Env #209: AVQAV WRSAT ETLAG;
    Env #210: VWRSA TETLA GAWGD;
    Env #211: ATETL AGAWG DLWET;
    Env #212: LAGAW GDLWE TLRRG;
    Env #213: WGDLW ETLRR GGRWI;
    Env #214: WETLR RGGRW ILAIP;
    Env #215: RRGGR WILAI PRRIR;
    Env #216: RWILA IPRRI RQGLE;
    Env #217: AIPRR IRQGL ELTLL

  • SIVmac239 Gag ( Overlapping peptide peptide library )

    Gag #1: MGVRN SVLSG KKADE;
    Gag #2: NSVLS GKKAD ELEKI;
    Gag #3: SGKKA DELEK IRLRP;
    Gag #4: ADELE KIRLR PNGKK;
    Gag #5: EKIRL RPNGK KKYML;
    Gag #6: LRPNG KKKYM LKHVV;
    Gag #7: GKKKY MLKHV VWAAN;
    Gag #8: YMLKH VVWAA NELDR;
    Gag #9: HVVWA ANELD RFGLA;
    Gag #10: AANEL DRFGL AESLL;
    Gag #11: LDRFG LAESL LENKE;
    Gag #12: GLAES LLENK EGCQK;
    Gag #13: SLLEN KEGCQ KILSV;
    Gag #14: NKEGC QKILS VLAPL;
    Gag #15: CQKIL SVLAP LVPTG;
    Gag #16: LSVLA PLVPT GSENL ;
    Gag #17: APLVP TGSEN LKSLY;
    Gag #18: PTGSE NLKSL YNTVC;
    Gag #19: ENLKS LYNTV CVIWC;
    Gag #20: SLYNT VCVIW CIHAE;
    Gag #21: NTVCV IWCIH AEEKV;
    Gag #22: VIWCI HAEEK VKHTE;
    Gag #23: IHAEE KVKHT EEAKQ;
    Gag #24: EKVKH TEEAK QIVQR;
    Gag #25: HTEEA KQIVQ RHLVV;
    Gag #26: AKQIV QRHLV VETGT;
    Gag #27: VQRHL VVETG TTETM;
    Gag #28: LVVET GTTET MPKTS;
    Gag #29: TGTTE TMPKT SRPTA;
    Gag #30: ETMPK TSRPT APSSG;
    Gag #31: KTSRP TAPSS GRGGN;
    Gag #32: PTAPS SGRGG NYPVQ;
    Gag #33: SSGRG GNYPV QQIGG;
    Gag #34: GGNYP VQQIG GNYVH;
    Gag #35: PVQQI GGNYV HLPLS;
    Gag #36: IGGNY VHLPL SPRTL;
    Gag #37: YVHLP LSPRT LNAWV;
    Gag #38: PLSPR TLNAW VKLIE;
    Gag #39: RTLNA WVKLI EEKKF;
    Gag #40: AWVKL IEEKK FGAEV;
    Gag #41: LIEEK KFGAE VVPGF;
    Gag #42: KKFGA EVVPG FQALS;
    Gag #43: AEVVP GFQAL SEGCT;
    Gag #44: PGFQA LSEGC TPYDI;
    Gag #45: ALSEG TPYDI NQMLN;
    Gag #46: GCTYP DINQM LNCVG;
    Gag #47: YDINQ MLNCV GDHQA;
    Gag #48: QMLNC VGDHQ AAMQI;
    Gag #49: CVGDH QAAMQ IIRDI;
    Gag #50: HQAAM QIIRD IINEE;
    Gag #51: MQIIR DIINE EAADW;
    Gag #52: RDIIN EEAAD WDLQH;
    Gag #53: NEEAA DWDLQ HPQPA;
    Gag #54: ADWDL QHPQP APQQG;
    Gag #55: LQHPQ PAPQQ GQLRE;
    Gag #56: QPAPQ QGQLR EPSGS;
    Gag #57: QQGQL REPSG SDIAG;
    Gag #58: LREPS GSDIA GTTSS;
    Gag #59: SGSDI AGTTS SVDEQ;
    Gag #60: IAGTT SSVDE QIQWM;
    Gag #61: TSSVD EQIQW MYRQQ;
    Gag #62: DEQIQ WMYRQ QNPIP;
    Gag #63: QWMYR QQNPI PVGNI;
    Gag #64: RQQNP IPVGN IYRRW;
    Gag #65: PIPVG NIYRR WIQLG;
    Gag #66: GNIYR RWIQL GLQKC;
    Gag #67: RRWIQ LGLQK CVRMY;
    Gag #68: QLGLQ KCVRM YNPTN ;
    Gag #69: QKCVR MYNPT NILDV;
    Gag #70: RMYNP TNILD VKQGP;
    Gag #71: PTNIL DVKQG PKEPF;
    Gag #72: LDVKQ GPKEP FQSYV;
    Gag #73: QGPKE PFQSY VDRFY;
    Gag #74: EPFQS YVDRF YKSLR;
    Gag #75: SYVDR FYKSL RAEQT;
    Gag #76: RFYKS LRAEQ TDAAV;
    Gag #77: SLRAE QTDAA VKNWM;
    Gag #78: EQTDA AVKNW MTQTL;
    Gag #79: AAVKN WMTQT LLIQN;
    Gag #80: NWMTQ TLLIQ NANPD;
    Gag #81: QTLLI QNANP DCKLY;
    Gag #82: IQNAN PDCKL VLKGL;
    Gag #83: NPDCK LVLKG LGVNP;
    Gag #84: KLVLK GLGVN PTLEE;
    Gag #85: LEEML TACQG VGGPG;
    Gag #86: VNPTL EEMLT ACQGV;
    Gag #87: LEEML TACQG VGGPG;
    Gag #88: LTACQ GVGGP GQKAR;
    Gag #89: QGVGG PGQKA RLMAE;
    Gag #90: GPGQK ARLMA EALKE;
    Gag #91: KARLM AEALK EALAP;
    Gag #92: MAEAL KEALA PVPIP;
    Gag #93: LKEAL APVPI PFAAA;
    Gag #94: LAPVP IPFAA AQQRG;
    Gag #95: PIPFA AAQQR GPRKP;
    Gag #96: AAAQQ RGPRK PIKCW;
    Gag #97: QRGPR KPIKC WNCGK;
    Gag #98: RKPIK CWNCG KEGHS;
    Gag #99: KCWNC GKEGH SARQC;
    Gag #100: CGKEG HSARQ CRAPR;
    Gag #101: GHSAR QCRAP RRQGC;
    Gag #102: RQCRA PRRQG CWKCG;
    Gag #103: APRRQ GCWKC GKMDH;
    Gag #104: QGCWK CGKMD HVMAK;
    Gag #105: KCGKM DHVMA KCPDR;
    Gag #106: MDHVM AKCPD RQAGF;
    Gag #107: MAKCP DRQAG FLGLG;
    Gag #108: PDRQA GFLGL GPWGK;
    Gag #109: AGFLG LGPWG KKPRN;
    Gag #110: GLGPW GKKPR NFPMA;
    Gag #111: WGKKP RNFPM AQVHQ;
    Gag #112: PRNFP MAQVH QGLMP;
    Gag #113: PMAQV HQGLM PTAPP;
    Gag #114: VHQGL MPTAP PEDPA;
    Gag #115: LMPTA PPEDP AVDLL;
    Gag #116: APPED PAVDL LKNYM;
    Gag #117: DPAVD LLKNY MQLGK;
    Gag #118: DLLKN YMQLG KQQRE;
    Gag #119: NYMQL GKQQR EKQRE;
    Gag #120: LGKQQ REKQR ESREK;
    Gag #121: QREKQ RESRE KPYKE;
    Gag #122: QRESR EKPYK EVTED;
    Gag #123: REKPY KEVTE DLLHL;
    Gag #124: YKEVT EDLLH LNSLF;
    Gag #125: TEDLL HLNSL FGGDQ

  • SIVmac239 Nef ( Overlapping peptide peptide library )

    Nef #1: MGGAI SMRRS RPSGD;
    Nef #2: ISMRR SRPSG DLRQR;
    Nef #3: RSRPS GDLRQ RLLRA;
    Nef #4: SGDLR QRLLR ARGET;
    Nef #5: RQRLL RARGE TYGRL;
    Nef #6: LRARG ETYGR LLGEV;
    Nef #7: GETYG RLLGE VEDGY;
    Nef #8: GRLLG EVEDG YSQSP;
    Nef #9: GEVED GYSQS PGGLD;
    Nef #10: DGYSQ SPGGL DKGLS;
    Nef #11: QSPGG LDKGL SSLSC;
    Nef #12: GLDKG LSSLS CEGQK;
    Nef #13: GLSSL SCEGQ KYNQG;
    Nef #14: LSCEG QKYNQ GQYMN;
    Nef #15: GQKYN QGQYM NTPWR;
    Nef #16: NQGQY MNTPW RNPAE;
    Nef #17: YMNTP WRNPA EEREK;
    Nef #18: PWRNP AEERE KLAYR;
    Nef #19: PAEER EKLAY RKQNM;
    Nef #20: REKLA YRKQN MDDID;
    Nef #21: EKLAY RKQNM DDIDE;
    Nef #22: YRKQN MDDID EEDDD;
    Nef #23: NMDDI DEEDD DLVGV;
    Nef #24: IDEED DDLVG VSVRP;
    Nef #25: DDDLV GVSVR PKVPL;
    Nef #26: VGVSV RPKVP LRTMS;
    Nef #27: VRPKV PLRTM SYKLA;
    Nef #28: VPLRT MSYKL AIDMS;
    Nef #29: TMSYK LAIDM SHFIK;
    Nef #30: KLAID MSHFI KEKGG;
    Nef #31: DMSHF IKEKG GLEGI;
    Nef #32: FIKEK GGLEG IYYSA;
    Nef #33: KGGLE GIYYS ARRHR;
    Nef #34: EGIYY SARRH RILDI;
    Nef #35: YSARR HRILD IYLEK;
    Nef #36: RHRIL DIYLE KEEGI;
    Nef #37: LDIYL EKEEG IIPDW;
    Nef #38: LEKEE GIIPD WQDYT;
    Nef #39: EGIIP DWQDY TSGPG;
    Nef #40: PDWQD YTSGP GIRYP;
    Nef #41: DYTSG PGIRY PKTFG;
    Nef #42: GPGIR YPKTF GWLWK;
    Nef #43: RYPKT FGWLW KLVPV;
    Nef #44: TFGWL WKLVP VNVSD;
    Nef #45: LWKLV PVNVS DEAQE;
    Nef #46: VPVNV SDEAQ EDEEH;
    Nef #47: VSDEA QEDEE HYLMH;
    Nef #48: AQEDE EHYLM HPAQT;
    Nef #49: EEHYL MHPAQ TSQWD;
    Nef #50: LMHPA QTSQW DDPWG;
    Nef #51: AQTSQ WDDPW GEVLA;
    Nef #52: QWDDP WGEVL AWKFD;
    Nef #53: PWGEV LAWKF DPTLA;
    Nef #54: VLAWK FDPTL AYTYE;
    Nef #55: KFDPT LAYTY EAYVR;
    Nef #56: TLAYT YEAYV RYPEE;
    Nef #57: TYEAY VRYPE EFGSK;
    Nef #58: YVRYP EEFGS KSGLS;
    Nef #59: PEEFG SKSGL SEEEV;
    Nef #60: GSKSG LSEEE VRRRL;
    Nef #61: GLSEE EVRRR LTARG;
    Nef #62: EEVRR RLTAR GLLNM;
    Nef #63: RRLTA RGLLN MADKK;
    Nef #64: ARGLL NMADK KETR

  • SIVmac239 Pol ( Overlapping peptide peptide library )

    pol #1: VLELW ERGTL CKAMQ;
    pol #2: WERGT LCKAM QSPKK;
    pol #3: WERGT LCKAM QSPKK;
    pol #4: AMQSP KKTGM LEMWK;
    pol #5: PKKTG MLEMW KNGPC;
    pol #6: GMLEM WKNGP CYGQM;
    pol #7: MWKNG PCYGQ MPRQT;
    pol #8: GPCYG QMPRQ TGGFF;
    pol #9: GQMPR QTGGF FRPWS;
    pol #10: RQTGG FFRPW SMGKE;
    pol #11: GFFRP WSMGK EAPQF;
    pol #12: PWSMG KEAPQ FPHGS;
    pol #13: GKEAP QFPHG SSASG;
    pol #14: PQFPH GSSAS GADAN;
    pol #15: HGSSA SGADA NCSPR;
    pol #16: ASGAD ANCSP RGPSC;
    pol #17: DANCS PRGPS CGSAK;
    pol #18: SPRGP SCGSA KELHA;
    pol #19: PSCGS AKELH AVGQA;
    pol #20: SAKEL HAVGQ AAERK;
    pol #21: LHAVG QAAER KAERK;
    pol #22: GQAAE RKAER KQREA;
    pol #23: ERKAE RKQRE ALQGG;
    pol #24: ERKQR EALQG GDRGF;
    pol #25: REALQ GGDRG FAAPQ;
    pol #26: QGGDR GFAAP QFSLW;
    pol #27: RGFAA PQFSL WRRPV;
    pol #28: APQFS LWRRP VVTAH;
    pol #29: SLWRR PVVTA HIEGQ;
    pol #30: RPVVT AHIEG QPVEV;
    pol #31: TAHIE GQPVE VLLDT;
    pol #32: EGQPV EVLLD TGADD;
    pol #33: VEVLL DTGAD DSIVT;
    pol #34: LDTGA DDSIV TGIEL;
    pol #35: ADDSI VTGIE LGPHY;
    pol #36: IVTGI ELGPH YTPKI;
    pol #37: IELGP HYTPK IVGGI;
    pol #38: PHYTP KIVGG IGGFI;
    pol #39: PKIVG GIGGF INTKE;
    pol #40: GGIGG FINTK EYKNV;
    pol #41: GFINT KEYKN VEIEV;
    pol #42: TKEYK NVEIF VLGKR;
    pol #43: KNVEI EVLGK RIKGT;
    pol #44: IEVLG KRIKG TIMTG;
    pol #45: GKRIK GTIMT GDTPI;
    pol #46: KGTIM TGDTP INIFG;
    pol #47: MTGDT PINIF GRNLL;
    pol #48: TPINI FGRNL LTALG;
    pol #49: IFGRN LLTAL GMSLN;
    pol #50: NLLTA LGMSL NFPIA;
    pol #51: ALGMS LNFPI AKVEP;
    pol #52: SLNFP IAKVE PVKVA;
    pol #53: PIAKV EPVKV ALKPG;
    pol #54: VEPVK VALKP GKDGP;
    pol #55: KVALK PGKDG PKLKQ;
    pol #56: KPGKD GPKLK QWPLS;
    pol #57: DGPKL KQWPL SKEKI;
    pol #58: LKQWP LSKEK IVALR;
    pol #59: PLSKE KIVAL REICE;
    pol #60: EKIVA LREIC EKMEK;
    pol #61: ALREI CEKME KDGQL;
    pol #62: ICEKM EKDGQ LEEAP;
    pol #63: MEKDG QLEEA PPTNP;
    pol #64: GQLEE APPTN PYNTP;
    pol #65: EAPPT NPYNT PTFAI;
    pol #66: TNPYN TPTFA IKKKD;
    pol #67: NTPTF AIKKK DKNKW;
    pol #68: FAIKK KDKNK WRMLI;
    pol #69: KKDKN KWRML IDFRE;
    pol #70: NKWRM LIDFR ELNRV;
    pol #71: MLIDF RELNR VTQDF;
    pol #72: FRELN RVTQD FTEVQ;
    pol #73: NRVTQ DFTEV QLGIP;
    pol #74: QDFTE VQLGI PHPAG;
    pol #75: EVQLG IPHPA GLAKR;
    pol #76: GIPHP AGLAK RKRIT;
    pol #77: PAGLA KRKRI TVLDI;
    pol #78: AKRKR ITVLD IGDAY;
    pol #79: RITVL DIGDA YFSIP;
    pol #80: LDIGD AYFSI PLDEE;
    pol #81: DAYFS IPLDE EFRQY;
    pol #82: SIPLD EEFRQ YTAFT;
    pol #83: DEEFR QYTAF TLPSV;
    pol #84: RQYTA FTLPS VNNAE;
    pol #85: AFTLP SVNNA EPGKR;
    pol #86: PSVNN AEPGK RYIYK;
    pol #87: NAEPG KRYIY KVLPQ;
    pol #88: GKRYI YKVLP QGWKG;
    pol #89: IYKVL PQGWK GSPAI;
    pol #90: LPQGW KGSPA IFQYT;
    pol #91: WKGSP AIFQY TMRHV;
    pol #92: PAIFQ YTMRH VLEPF;
    pol #93: QYTMR HVLEP FRKAN;
    pol #94: RHVLE PFRKA NPDVT;
    pol #95: EPFRK ANPDV TLVQY;
    pol #96: KANPD VTLVQ YMDDI;
    pol #97: DVTLV QYMDD ILIAS;
    pol #98: VQYMD DILIA SDRTD;
    pol #99: DDILI ASDRT DLEHD;
    pol #100: IASDR TDLEH DRVVL;
    pol #101: RTDLE HDRVV LQSKE;
    pol #102: EHDRV VLQSK ELLNS;
    pol #103: VVLQS KELLN SIGFS;
    pol #104: SKELL NSIGF STPEE;
    pol #105: LNSIG FSTPE EKFQK;
    pol #106: GFSTP EEKFQ KDPPF;
    pol #107: PEEKF QKDPP FQWMG;
    pol #108: FQKDP PFQWM GYELW;
    pol #109: PPFQW MGYEL WPTKW;
    pol #110: WMGYE LWPTK WKLQK;
    pol #111: ELWPT KWKLQ KIELP;
    pol #112: TKWKL QKIEL PQRET;
    pol #113: LQKIE LPQRE TWTVN;
    pol #114: ELPQR ETWTV NDIQK;
    pol #115: RETWT VNDIQ KLVGV;
    pol #116: TVNDI QKLVG VLNWA;
    pol #117: IQKLV GVLNW AAQIY;
    pol #118: VGVLN WAAQI YPGIK;
    pol #119: NWAAQ IYPGI KTKHL;
    pol #120: QIYPG IKTKH LCRLI;
    pol #121: GIKTK HLCRL IRGKM;
    pol #122: KHLCR LIRGK MTLTE;
    pol #123: RLIRG KMTLT EEVQW;
    pol #124: GKMTL TEEVQ WTEMA;
    pol #125: LTEEV QWTEM AEAEY;
    pol #126: VQWTE MAEAE YEENK;
    pol #127: EMAEA EYEEN KIILS;
    pol #128: AEYEE NKIIL SQEQE ;
    pol #129: ENKII LSQEQ EGCYY;
    pol #130: ILSQE QEGCY YQEGK;
    pol #131: EQEGC YYQEG KPLEA;
    pol #132: CYYQE GKPLE ATVIK;
    pol #133: EGKPL EATVI KSQDN;
    pol #134: LEATV IKSQD NQWSY;
    pol #135: VIKSQ DNQWS YKIHQ;
    pol #136: QDNQW SYKIH QEDKI;
    pol #137: WSYKI HQEDK ILKVG;
    pol #138: IHQED KILKV GKFAK;
    pol #139: DKILK VGKFA KIKNT;
    pol #140: KVGKF AKIKN THTNG;
    pol #141: FAKIK NTHTN GVRLL;
    pol #142: KNTHT NGVRL LAHVI;
    pol #143: TNGVR LLAHV IQKIG;
    pol #144: RLLAH VIQKI GKEAI;
    pol #145: HVIQK IGKEA IVIWG;
    pol #146: KIGKE AIVIW GQVPK;
    pol #147: EAIVI WGQVP KFHLP;
    pol #148: IWGQV PKFHL PVEKD;
    pol #149: VPKFH LPVEK DVWEQ;
    pol #150: HLPVE KDVWE QWWTD;
    pol #151: EKDVW EQWWT DYWQV;
    pol #152: WEQWW TDYWQ VTWIP;
    pol #153: WTDYW QVTWI PEWDF;
    pol #154: WQVTW IPEWD FISTP;
    pol #155: WIPEW DFIST PPLVR;
    pol #156: WDFIS TPPLV RLVFN;
    pol #157: STPPL VRLVF NLVKD;
    pol #158: LVRLV FNLVK DPIEG;
    pol #159: VFNLV KDPIE GEETY;
    pol #160: VKDPI EGEET YYTDG;
    pol #161: IEGEE TYYTD GSCNK;
    pol #162: ETYYT DGSCN KQSKE;
    pol #163: TDGSC NKQSK EGKAG;
    pol #164: CNKQS KEGKA GYITD;
    pol #165: SKEGK AGYIT DRGKD;
    pol #166: KAGYI TDRGK DKVKV;
    pol #167: ITDRG KDKVK VLEQT;
    pol #168: GKDKV KVLEQ TTNQQ;
    pol #169: VKVLE QTTNQ QAELE;
    pol #170: EQTTN QQAEL EAFLM;
    pol #171: NQQAE LEAFL MALTD;
    pol #172: ELEAF LMALT DSGPK;
    pol #173: FLMAL TDSGP KANII;
    pol #174: LTDSG PKANI IVDSQ;
    pol #175: GPKAN IIVDS QYVMG;
    pol #176: NIIVD SQYVM GIITG;
    pol #177: DSQYV MGIIT GCPTE;
    pol #178: VMGII TGCPT ESESR;
    pol #179: ITGCP TESES RLVNQ;
    pol #180: PTESE SRLVN QIIEE;
    pol #181: ESRLV NQIIE EMIKK;
    pol #182: VNQII EEMIK KSEIY;
    pol #183: IEEMI KKSEI YVAWV;
    pol #184: IKKSE IYVAW VPAHK;
    pol #185: EIYVA WVPAH KGIGG;
    pol #186: AWVPA HKGIG GNQEI;
    pol #187: AHKGI GGNQE IDHLV;
    pol #188: IGGNQ EIDHL VSQGI;
    pol #189: QEIDH LVSQG IRQVL;
    pol #190: HLVSQ GIRQV LFLEK;
    pol #191: QGIRQ VLFLE KIEPA;
    pol #192: QVLFL EKIEP AQEEH;
    pol #193: LEKIE PAQEE HDKYH;
    pol #194: EPAQE EHDKY HSNVK;
    pol #195: EEHDK YHSNV KELVF;
    pol #196: KYHSN VKELV FKFGL;
    pol #197: NVKEL VFKFG LPRIV;
    pol #198: LVFKF GLPRI VARQI;
    pol #199: FGLPR IVARQ IVDTC;
    pol #200: RIVAR QIVDT CDKCH;
    pol #201: RQIVD TCDKC HQKGE;
    pol #202: DTCDK CHQKG EAIHG;
    pol #203: KCHQK GEAIH GQANS;
    pol #204: KGEAI HGQAN SDLGT;
    pol #205: IHGQA NSDLG TWQMD;
    pol #206: ANSDL GTWQM DCTHL;
    pol #207: LGTWQ MDCTH LEGKI;
    pol #208: QMDCT HLEGK IIIVA;
    pol #209: THLEG KIIIV AVHVA;
    pol #210: GKIII VAVHV ASGFI;
    pol #211: IVAVH VASGF IEAEV;
    pol #212: HVASG FIEAE VIPQE;
    pol #213: GFIEA EVIPQ ETGRQ;
    pol #214: AEVIP QETGR QTALF;
    pol #215: PQETG RQTAL FLLKL;
    pol #216: GRQTA LFLLK LAGRW;
    pol #217: ALFLL KLAGR WPITH;
    pol #218: LKLAG RWPIT HLHTD;
    pol #219: GRWPI THLHT DNGAN;
    pol #220: ITHLH TDHGA NFASQ;
    pol #221: HTDNG ANFAS QEVKM;
    pol #222: GANFA SQEVK MVAWW;
    pol #223: ASQEV KMVAW WAGIE;
    pol #224: VKMVA WWAGI EHTFG;
    pol #225: AWWAG IEHTF GVPYN;
    pol #226: GIEHT FGVPY NPQSQ;
    pol #227: TFGVP YNPQS QGVVE;
    pol #228: PYNPQ SQGVV EAMNH;
    pol #229: QSQGV VEAMN HHLKN;
    pol #230: VVEAM NHHLK NQIDR;
    pol #231: MNHHL KNQID RIREQ;
    pol #232: LKNQI DRIRE QANSV;
    pol #233: IDRIR EQANS VETIV;
    pol #234: REQAN SVETI VLMAV;
    pol #235: NSVET IVLMA VHCMN;
    pol #236: TIVLM AVHCM NFKRR;
    pol #237: MAVHC MNFKR RGGIG;
    pol #238: CMNFK RRGGI GDMTP;
    pol #239: KRRGG IGDMT PAERL;
    pol #240: GIGDM TPAER LINMI;
    pol #241: MTPAE RLINM ITTEQ;
    pol #242: ERLIN MITTE QEIQF;
    pol #243: NMITT EQEIQ FQQSK;
    pol #244: TEQEI QFQQS KNSKF;
    pol #245: IQFQQ SKNSK FKNFR;
    pol #246: QSKNS KFKNF RVYYR;
    pol #247: SKFKN FRVYY REGRD;
    pol #248: NFRVY YREGR DQLWK;
    pol #249: YYREG RDQLW KGPGE;
    pol #250: GRDQL WKGPG ELLWK;
    pol #251: LWKGP GELLW KGEGA;
    pol #252: PGELL WKGEG AVILK;
    pol #253: LWKGE GAVIL KVGTD;
    pol #254: EGAVI LKVGT DIKVV;
    pol #255: ILKVG TDIKV VPRRK;
    pol #256: GTDIK VVPRR KAKII;
    pol #257: KVVPR RKAKI IKDYG;
    pol #258: RRKAK IIKDY GGGKE;
    pol #259: KIIKD YGGGK EVDSS;
    pol #260: DYGGG KEVDS SSHME;
    pol #261: GKEVD SSSHM EDTGE;
    pol #262: DSSSH MEDTG EAREVA

  • SIVmac239 Rev ( Overlapping peptide peptide library )

    Rev #1: MSNHE REEEL RKRLR;
    Rev #2: EREEE LRKRL RLIHL;
    Rev #3: ELRKR LRLIH LLHQT;
    Rev #4: RLRLI HLLHQ TNPYP;
    Rev #5: IHLLH QTNPY PTGPG;
    Rev #6: HQTNP YPTGP GTANQ;
    Rev #7: PYPTG PGTAN QRRQR;
    Rev #8: GPGTA NQRRQ RKRRW;
    Rev #9: ANQRR QRKRR WRRRW;
    Rev #10: RQRKR RWRRR WQQLL;
    Rev #11: RRWRR RWQQL LALAD;
    Rev #12: RRWQQ LLALA DRIYS;
    Rev #13: QLLAL ADRIY SFPDP;
    Rev #14: LADRI YSFPD PPTDT;
    Rev #15: IYSFP DPPTD TPLDL;
    Rev #16: PDPPT DTPLD LAIQQ;
    Rev #17: TDTPL DLAIQ QLQNL;
    Rev #18: LDLAI QQLQN LAIES;
    Rev #19: IQQLQ NLAIE SIPDP;
    Rev #20: QNLAI ESIPD PPTNT;
    Rev #21: IESIP DPPTN TPEAL;
    Rev #22: PDPPT NTPEA LCDPT;
    Rev #23: TNTPE ALCDP TEDSR;
    Rev #24: EALCD PTEDS RSPQD

  • SIVmac239 Tat ( Overlapping peptide peptide library )

    Tat #1: METPL REQEN SLESS;
    Tat #2: LREQE NSLES SNERS;
    Tat #3: ENSLE SSNER SSCLS;
    Tat #4: ESSNE RSSCI SEADA;
    Tat #5: ERSSC ISEAD ASTPE;
    Tat #6: CISEA DASTP ESANL;
    Tat #7: ADAST PESAN LGEEI;
    Tat #8: TPESA NLGEE ILSQL;
    Tat #9: ANLGE EILSQ LYRPL;
    Tat #10: EEILS QLYRP LEACY;
    Tat #11: SQLYR PLEAC YNTCY;
    Tat #12: RPLEA CYNTC YCKKC;
    Tat #13: ACYNT CYCKK CCYHC;
    Tat #14: TCYCK KCCYH CQFCF;
    Tat #15: KKCCY HCQFC FLKKG;
    Tat #16: YHCQF CFLKK GLGIC;
    Tat #17: FCFLK KGLGI CYEQS;
    Tat #18: KKGLG ICYEQ SRKRR;
    Tat #19: GICYE QSRKR RRTPK;
    Tat #20: EQSRK RRRTP KKAKA;
    Tat #21: KRRRT PKKAK ANTSS;
    Tat #22: TPKKA KANTS SASNK;
    Tat #23: AKANT SSASN KPISN;
    Tat #24: TSSAS NKPIS NRTRH;
    Tat #25: SNKPI SNRTR HCQPE;
    Tat #26: ISNRT RHCQP EKAKK;
    Tat #27: TRHCQ PEKAK KETVE;
    Tat #28: QPEKA KKETV EKAVA;
    Tat #29: AKKET VEKAV ATAPG;
    Tat #30: ETVEK AVATA PGLGR

  • SIVmac239 Vif ( Overlapping peptide peptide library )

    Vif #1: MEEEK RWIAV PTWRI;
    Vif #2: KRWIA VPTWR IPERL;
    Vif #3: AVPTW RIPER LERWH;
    Vif #4: WRIPE RLERW HSLIK;
    Vif #5: ERLER WHSLI KYLKY;
    Vif #6: RWHSL IKYLK YKTKD;
    Vif #7: LIKYL KYKTK DLQKV;
    Vif #8: LKYKT KDLQK VCYVP;
    Vif #9: TKDLQ KVCYV PHFKV;
    Vif #10: QKVCY VPHFK VGWAW;
    Vif #11: YVPHF KVGWA WWTCS;
    Vif #12: FKVGW AWWTC SRVIF;
    Vif #13: WAWWT CSRVI FPLQE;
    Vif #14: TCSRV IFPLQ EGSHL;
    Vif #15: VIFPL QEGSH LEVQG;
    Vif #16: LQEGS HLEVQ GYWHL;
    Vif #17: SHLEV QGYWH LTPEK;
    Vif #18: VQGYW HLTPE KGWLS;
    Vif #19: WHLTP EKGWL STYAV;
    Vif #20: PEKGW LSTYA VRITW;
    Vif #21: WLSTY AVRIT WYSKN;
    Vif #22: YAVRI TWYSK NFWTD;
    Vif #23: ITWYS KNFWT DVTPN;
    Vif #24: SKNFW TDVTP NYADI;
    Vif #25: WTDVT PNYAD ILLHS;
    Vif #26: TPNYA DILLH STYFP;
    Vif #27: ADILL HSTYF PCFTA;
    Vif #28: LHSTY FPCFT AGEVR;
    Vif #29: YFPCF TAGEV RRAIR;
    Vif #30: FTAGE VRRAI RGEQL;
    Vif #31: EVRRA IRGEQ LLSCC;
    Vif #32: AIRGE QLLSC CRFPR;
    Vif #33: EQLLS CCRFP RAHKY;
    Vif #34: SCCRF PRAHK YQVPS;
    Vif #35: FPRAH KYQVP SLQYL;
    Vif #36: HKYQV PSLQY LALKV;
    Vif #37: VPSLQ YLALK VVSDV;
    Vif #38: QYLAL KVVSD VRSQG;
    Vif #39: LKVVS DVRSQ GENPT;
    Vif #40: SDVRS QGENP TWKQW;
    Vif #41: SQGEN PTWKQ WRRDN;
    Vif #42: NPTWK QWRRD NRRGL;
    Vif #43: KQWRR DNRRG LRMAK;
    Vif #44: RDNRR GLRMA KQNSR;
    Vif #45: RGLRM AKQNS RGDKQ;
    Vif #46: MAKQN SRGDK QRGGK;
    Vif #47: NSRGD KQRGG KPPTK;
    Vif #48: DKQRG GKPPT KGANF;
    Vif #49: GGKPP TKGAN FPGLA;
    Vif #50: PTKGA NFPGL AKVLG;
    Vif #51: GANFP GLAKV LGILA

  • SIVmac239 Vpr ( Overlapping peptide peptide library )

    vpr #1: MEERP PENEG PQREP;
    vpr #2: PPENE GPQRE PWDEW;
    vpr #3: EGPQR EPWDE WVVEV;
    vpr #4: REPWD EWVVE VLEEL;
    vpr #5: DEWVV EVLEE LKEEA;
    vpr #6: VEVLE ELKEE ALKHF;
    vpr #7: EELKE EALKH FDPRL;
    vpr #8: EEALK HFDPR LLTAL;
    vpr #9: KHFDP RLLTA LGNHI;
    vpr #10: PRLLT ALGNH IYNRH;
    vpr #11: TALGN HIYNR HGDTL;
    vpr #12: NHIYN RHGDT LEGAG;
    vpr #13: NRHGD TLEGA GELIR;
    vpr #14: DTLEG AGELI RILQR;
    vpr #15: GAGEL IRILQ RALFM;
    vpr #16: LIRIL QRALF MHFRG;
    vpr #17: LQRAL FMHFR GGCIH;
    vpr #18: LFMHF RGGCI HSRIG;
    vpr #19: FRGGC IHSRI GQPGG;
    vpr #20: CIHSR IGQPG GGNPL;
    vpr #21: RIGQP GGGNP LSAIP;
    vpr #22: PGGGN PLSAI PPSRS;
    vpr #23: GGNPL SAIPP SRSML

  • SIVmac239 Vpx ( Overlapping peptide peptide library )

    vpx #1: MSDPR ERIPP GNSGE;
    vpx #2: RERIP PGNSG EETIG;
    vpx #3: PPGNS GEETI GEAFE;
    vpx #4: SGEET IGEAF EWLNR;
    vpx #5: TIGEA FEWLN RTVEE;
    vpx #6: AFEWL NRTVE EINRE;
    vpx #7: LNRTV EEINR EAVNH;
    vpx #8: VEEIN REAVN HLPRE;
    vpx #9: NREAV NHLPR ELIFQ;
    vpx #10: VNHLP RELIF QVWQR;
    vpx #11: PRELI FQVWQ RSWEY;
    vpx #12: IFQVW QRSWE YWHDE;
    vpx #13: WQRSW EYWHD EQGMS;
    vpx #14: WEYWH DEQGM SPSYV;
    vpx #15: HDEQG MSPSY VKYRY;
    vpx #16: GMSPS YVKYR YLCLI;
    vpx #17: SYVKY RYLCL IQKAL;
    vpx #18: YRYLC LIQKA LFMHC;
    vpx #19: CLIQK ALFMH CKKGC;
    vpx #20: KALFM HCKKG CRCLG;
    vpx #21: MHCKK GCRCL GEGHG;
    vpx #22: KGCRC LGEGH GAGGW;
    vpx #23: CLGEG HGAGG WRPGP;
    vpx #24: GHGAG GWRPG PPPPP;
    vpx #25: GGWRP GPPPP PPPGL;
    vpx #26: GWRPG PPPPP PPGLA


Last updated: 2012-12-14T18:47:02.528-06:00

Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016